Comparative Pharmacology
Head-to-head clinical analysis: PREFEST versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREFEST versus STILPHOSTROL.
PREFEST vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREFEST combines estradiol (an estrogen) and norgestimate (a progestin). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), leading to gene transcription regulation, which promotes proliferation of endometrial tissue and secondary sexual characteristics. Norgestimate, a progestin, suppresses gonadotropin secretion and inhibits ovulation, and also counteracts estrogen-induced endometrial hyperplasia by inducing secretory transformation and reducing mitotic activity.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet (estradiol 2 mg) orally once daily on days 1–3, then one tablet (estradiol 2 mg/norgestimate 0.09 mg) orally once daily on days 4–6; repeat cycle continuously.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Estradiol: 13-16 hours (terminal); estradiol valerate: 12-14 hours (prodrug hydrolysis rate-limiting); clinical context: once-daily dosing achieves steady-state in 5-7 days
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Renal: 50-60% as glucuronide conjugates; fecal: 5-10% as unconjugated metabolites; biliary: minor (<5%)
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category C
Category C
Estrogen/Progestin Combination Hormone Therapy
Estrogen